百特醫療 (BAX) 2017 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2017 年第二季財報電話會議。(接線員指示)提醒各位,本通話由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請此刻中斷連線。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • Clare Trachtman - Vice-President of Investor Relations

    Clare Trachtman - Vice-President of Investor Relations

  • Thank you, Candace. Good morning, and welcome to our second quarter 2017 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    謝謝你,Candace。各位早安,歡迎參加我們 2017 年第二季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's second quarter 2017 financial results, along with our updated outlook for 2017.

    今天上午的電話會議中,我們將討論百特 2017 年第二季財務結果,以及我們對 2017 年更新後的展望。

  • In addition, as previously mentioned, we will be providing an updated financial outlook for 2020 as compared to the expectations we laid out at our investor conference in May of 2016.

    此外,如先前所提及,我們也將提供更新後的 2020 年財務展望,並與我們在 2016 年 5 月投資人會議中提出的預期進行比較。

  • As a reminder, we have posted a supplemental presentation to complement this morning's discussion. This presentation, along with the related non-GAAP reconciliations, can be accessed on Baxter's external website in the Investors section under Events & Presentations.

    提醒各位,我們已上傳一份補充簡報,以配合今天上午的討論。該簡報以及相關的非 GAAP 調節表,可於百特對外網站的「投資人」專區中「活動與簡報(Events & Presentations)」項下取得。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contains forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    接下來,在開始我們的預先準備發言前,先提醒各位:本簡報(包括關於我們財務展望、新產品開發、業務開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期有重大差異之因素的更多細節,請參閱今日新聞稿及我們向 SEC 提交的文件。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已收錄於我們今早發布的財報新聞稿中,並可於我們網站取得。

  • Now I'd like to turn the call over to Joe. Joe?

    現在我想把電話交給 Joe。Joe?

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • Good morning, everyone, and thanks for joining us today. I will get started with a brief look at our second quarter results, then I will share some highlights reflecting the progress and potential of our ongoing business transformation, and conclude with an update to our 2020 guidance. After that, I will turn the call over to Jay, who will walk through our second quarter results and financial outlook in more detail. We'll close with Q&A.

    各位早安,感謝今天加入我們。我將先簡要回顧第二季業績,接著分享一些重點,反映我們持續推動的業務轉型之進展與潛力,最後更新我們的 2020 年指引。之後我會把電話交給 Jay,他將更詳細說明第二季結果與財務展望。最後我們將進行問答。

  • Baxter delivered another solid quarter, achieving top line sales growth of 1% on a reported basis and 2% on a constant currency basis. Operationally, Baxter's sales increased 3%, which excludes the impact of foreign exchange, net of competition for U.S. cyclophosphamide and the previously communicated strategic exits the company's undertaken.

    百特再度交出穩健的一季,營收在報告基礎上成長 1%,以固定匯率計成長 2%。就營運面而言,百特銷售成長 3%,此數字排除外匯影響,並扣除美國環磷醯胺(cyclophosphamide)競爭因素,以及公司先前已對外說明的策略性退出所帶來的影響。

  • Key top line drivers include a strong U.S. performance, include systems nutrition and anesthesia as well as steady global growth in PD and acute renal therapies.

    營收成長的主要驅動因素包括美國市場的強勁表現,涵蓋系統化營養與麻醉業務,以及腹膜透析(PD)與急性腎臟治療在全球的穩健成長。

  • On the bottom line, adjusted earnings were $0.63 per diluted share, increasing 37% over the prior-year period.

    在獲利方面,調整後每股盈餘為每股稀釋後 0.63 美元,較去年同期成長 37%。

  • This reflects solid top line growth, improved gross margins and the steady impact of our ongoing business transformation efforts.

    這反映了穩健的營收成長、毛利率改善,以及我們持續推動業務轉型所帶來的穩定效益。

  • A little over a year ago, we outlined our road map for achieving sustained top quartile performance. As far as this transformation, we created a foundation that is redefining how we do business and deliver value for our patients, employees and shareholders.

    大約一年前,我們提出了實現長期維持同業前四分位表現的路線圖。就這項轉型而言,我們建立了一個基礎,正在重新定義我們的營運方式,以及如何為病患、員工與股東創造價值。

  • To date, we have made great progress, rather, in executing this transformation and are focused on positioning the company for continued success. I will share a few recent highlights that support this objective.

    截至目前,我們在推動這項轉型的執行上已取得長足進展,並專注於讓公司具備持續成功的定位。我將分享幾項近期重點,以支持這個目標。

  • We expect to close our proposed acquisition of Claris Injectables imminently. This acquisition broadens our presence and prospects in generic injectable pharmaceuticals, and provides expanded capabilities in one of our core growth areas.

    我們預期將在近期完成對 Claris Injectables 的擬議收購。此收購將擴大我們在學名注射劑藥品領域的布局與前景,並在我們的核心成長領域之一提供更強的能力。

  • Claris brings us a product portfolio of more than 50 products on the market and a robust pipeline of more than 100 new products in development. We will continue to augment this business with strategic partnerships like the agreement we signed in the quarter with Dorizoe Lifesciences to accelerate the development of more than 20 generic injectables.

    Claris 將帶來超過 50 項已上市產品的產品組合,以及超過 100 項正在開發中的新產品之強勁研發管線。我們也將持續透過策略夥伴關係來強化此業務,例如本季我們與 Dorizoe Lifesciences 簽署協議,以加速超過 20 項學名注射劑的開發。

  • During the quarter, we also announced research and clinical development collaborations with leading institutions, Mayo Clinic and Ramot at Tel Aviv University and Tel Aviv Sourasky Medical Center, to transform patient care with new technologies and products across an array of therapeutic areas, including renal care and surgical care, respectively.

    本季期間,我們也宣布與領先機構展開研究與臨床開發合作,包括 Mayo Clinic,以及特拉維夫大學的 Ramot 與特拉維夫 Sourasky 醫學中心,透過新技術與產品在多個治療領域(分別包括腎臟照護與外科照護)推動病患照護的轉型。

  • We also received FDA guidance in the quarter, clarifying the regulatory pathway for a new home-based PD solutions generation system. This technology has the potential to remove some existing barriers to home-based dialysis, enabling more patients to experience the lifestyle benefits of home therapy.

    我們也在本季獲得 FDA 指導,釐清新一代居家腹膜透析(PD)溶液生成系統的法規途徑。此技術有潛力移除部分現有的居家透析障礙,使更多病患能享受居家治療在生活型態上的益處。

  • We will continue expanding our research and development pipeline with significant investment targeted to new product development and additional collaborations to accelerate growth through 2020 and beyond.

    我們將持續擴充研發管線,並加大投資,聚焦於新產品開發及更多合作,以加速 2020 年及其後的成長。

  • And while the pipeline continues to expand, we are also maintaining a steady tempo of new product launches, new indications and geographic expansions across our global portfolio.

    同時,在研發管線持續擴張之際,我們也維持穩定節奏,於全球產品組合中推出新產品、拓展新適應症並進行地理市場擴張。

  • Our progress and pace have also been reinforced by continued evolution in our operating structure and leadership.

    我們的進展與速度,也因營運架構與領導團隊的持續演進而更加鞏固。

  • Over the last few months, we've further built our -- built out, rather, our leadership team with some major names in new positions and some talented new players joining the company. With Paul Vibert's recent retirement, we are in process of simplifying our geographic structure into 3 regions: The Americas, including North and South America; EMEA, or Europe, Middle East and Africa; and Asia Pacific.

    過去幾個月,我們進一步擴充了領導團隊——更正,是完善了領導團隊——在新職位上延攬了幾位重量級人士,也有一些優秀的新成員加入公司。隨著 Paul Vibert 近期退休,我們正著手將地理架構簡化為三大區域:美洲(含北美與南美)、EMEA(即歐洲、中東與非洲)以及亞太地區。

  • Brik Eyre is now serving as President of our Americas region.

    Brik Eyre 現任我們美洲區總裁。

  • Onboarding this week is Andy Frye, our new President of Asia Pacific. He joins us from DKSH Healthcare, one of the largest service providers in Asia, where he served as the Global Head of Healthcare.

    本週到任的是 Andy Frye,他將擔任我們新的亞太區總裁。他來自 DKSH Healthcare(亞洲最大的服務供應商之一),先前擔任醫療保健全球主管(Global Head of Healthcare)。

  • Cristiano Franzi has been named our new President of EMEA effective September 1.

    Cristiano Franzi 已被任命為我們新的 EMEA 區總裁,並將於 9 月 1 日生效。

  • Most recently, Cristiano served as President, Minimally Invasive Therapies Group EMEA for Medtronic. Giuseppe Accogli now has an expanded role as President, Global Businesses, responsible for driving global growth through strategy, product development and marketing for the business franchises within Hospital Products and Renal.

    最近,Cristiano 在美敦力(Medtronic)擔任微創治療事業群 EMEA 區總裁。Giuseppe Accogli 現在擴大職責,擔任全球業務總裁(President, Global Businesses),負責透過策略、產品開發與行銷,推動醫院產品與腎臟事業內各業務特許經營(franchises)的全球成長。

  • And Sumant Ramachandra joined us in June as our new Chief Science and Technology officer. Sumant was most recently Senior Vice President and Head of R&D for Pfizer Essential Health.

    此外,Sumant Ramachandra 於 6 月加入我們,擔任新的首席科學與技術長。Sumant 最近的職務為輝瑞(Pfizer)Essential Health 研發資深副總裁暨研發主管。

  • This leadership team is aligned, energized and ready to lead the charge forward.

    這個領導團隊目標一致、充滿動能,並已準備好帶領公司持續向前。

  • In light of our progress, trajectory and potential, we're now prepared to update our 2020 guidance. We are projecting sales to grow approximately 4% on a compounded annual basis from 2016 to 2020. We expect a 2020 adjusted operating margin of approximately 20% and adjusted earnings of $3.25 to $3.40 per diluted share. Finally, we expect to generate free cash flow of approximately $2 billion.

    鑑於我們的進展、走勢與潛力,我們現在已準備更新 2020 年指引。我們預估 2016 年至 2020 年期間,銷售額將以約 4% 的年複合成長率成長。我們預期 2020 年調整後營業利益率約為 20%,調整後每股盈餘為每股稀釋後 3.25 至 3.40 美元。最後,我們預期將產生約 20 億美元的自由現金流。

  • We're pleased with these increases, and we'll continue to evaluate opportunities to accelerate this performance, both organically and inorganically. We continue to see business development playing a crucial role in building out our portfolio and pipeline, focused on key growth categories and adjacencies. This will be enabled by our healthy cash flow, allowing us to deploy capital to create value on both the top and bottom line. In parallel, we will remain relentless in our efforts to increase efficiency, process improvements, smart expanding and the engagement of all Baxter employees have been fundamental to our transformation to date and will continue to fuel a reinvestment and margin expansion in future quarters.

    我們對這些成長感到滿意,並將持續評估可加速此一表現的機會,無論是透過內生成長或外部併購。我們仍然認為業務開發在打造我們的產品組合與研發管線方面扮演關鍵角色,聚焦於主要成長類別及其相鄰領域。這將仰賴我們健康的現金流,使我們得以部署資本,在營收端與獲利端同時創造價值。同時,我們將持續不懈地提升效率與改善流程;迄今為止,審慎擴張以及全體百特員工的投入一直是我們轉型的基石,並將在未來幾季持續推動再投資與利潤率擴張。

  • In sum, we have arrived at the next phase of our transformation journey and, just like before, persistent, disciplined execution points the way forward. We have a sound strategy and our leadership team is fully engaged to help us realize our goals.

    總而言之,我們已進入轉型旅程的下一階段,而一如既往,持續且有紀律的執行將指引我們前行。我們擁有健全的策略,領導團隊也全力投入,協助我們實現目標。

  • Most importantly, we have exceptional talent across the entire company that embraces our mission to save and sustain patients' lives and advance our aspirations to deliver top quartile performance for all of our stakeholders.

    最重要的是,我們在全公司擁有卓越的人才,秉持拯救並維持病患生命的使命,並推進我們為所有利害關係人交出同業前四分位表現的願景。

  • Together, we are ready to set our sights higher.

    我們已準備好一起把目標定得更高。

  • With that, I'll pass it to Jay for a closer look at our financials.

    接下來,我把時間交給 Jay,請他更深入說明我們的財務表現。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Thanks, Joe, and good morning, everyone.

    謝謝你,Joe,各位早安。

  • As Joe mentioned, we're pleased with our second quarter results, reinforcing our confidence that we are on the right path to achieve our goal of sustaining top quartile performance.

    如 Joe 所提到的,我們對第二季的結果感到滿意,這也強化了我們的信心:我們正走在正確的道路上,以達成維持同業前四分位表現的目標。

  • Sales in the quarter increased 1% on a reported basis, 2% constant currency and 3% operationally in line with our expectations. The results were really driven by strength across many of our U.S. businesses and improving operational growth internationally.

    本季銷售額以報告基礎計增加 1%,以固定匯率計增加 2%,以營運基礎計增加 3%,符合我們的預期。這些結果主要來自我們多項美國業務的強勁表現,以及國際市場營運成長的改善。

  • On the bottom line, adjusted earnings were $0.63 per diluted share. This exceeded our guidance of $0.55 to $0.57 per share and reflects solid execution on the top line, the ongoing impacts from our business transformation efforts and a modest benefit from other income and a lower tax rate.

    在獲利端,調整後每股稀釋盈餘為 0.63 美元。此數字高於我們每股 0.55 至 0.57 美元的指引,反映了營收端的穩健執行、業務轉型措施的持續效益,以及其他收益與較低稅率帶來的些許助益。

  • Now I'll walk you through performance by business. I will be speaking to growth figures on an operational basis to provide a clearer understanding of underlying performance. As a reminder, our operational basis presentation excludes the impact of foreign exchange, U.S. cyclophosphamide and select strategic product exits.

    接下來我將帶各位檢視各業務的表現。為了更清楚呈現基本面表現,我將以營運基礎的成長數據進行說明。提醒各位,我們的營運基礎呈現排除外匯影響、美國 cyclophosphamide(環磷醯胺)以及部分策略性產品退出的影響。

  • Global sales for Hospital Products were $1.6 billion, advancing 4% operationally.

    醫院產品(Hospital Products)全球銷售額為 16 億美元,營運基礎成長 4%。

  • Breaking this out by business, sales in Fluid Systems were $607 million, up 6% operationally. Performance was primarily driven by strong sales of IV solutions in the U.S.

    按業務拆分,輸液系統(Fluid Systems)銷售額為 6.07 億美元,營運基礎成長 6%。表現主要由美國靜脈輸液(IV solutions)強勁銷售所帶動。

  • Moving to Integrated Pharmacy Solutions, or IPS, global sales were $568 million, increasing 4% operationally. Contributing to performance in the quarter was increased demand for the company's nutritional therapies in the U.S., driven by a temporary market disruption for select nutritional products.

    再看整合藥局解決方案(Integrated Pharmacy Solutions,IPS),全球銷售額為 5.68 億美元,營運基礎成長 4%。本季表現的貢獻之一,是美國對公司營養治療產品需求增加,原因在於部分營養產品出現短期市場供應中斷。

  • Sales for premixed injectable drugs also increased in the quarter, driven by recent launches and incremental pull-through of other premixed injectable products in our portfolio.

    預混注射劑藥品(premixed injectable drugs)本季銷售亦有所增加,主要受近期新品上市,以及我們產品組合中其他預混注射劑產品的帶動效應(pull-through)所驅動。

  • Moving to Surgical Care, which includes anesthesia and BioSurgery, total sales were $352 million, increasing 3% operationally. Performance in the quarter was fueled by strong U.S. growth for anesthesia and critical care products, driven by increased sales of BREVIBLOC, a fast-acting IV beta-blocker, and Transderm SCOP. We did experience a slight benefit in the quarter as the alternate supplier for Transderm SCOP returned to the market a bit later than expected.

    接著是外科照護(Surgical Care),包含麻醉與 BioSurgery,總銷售額為 3.52 億美元,營運基礎成長 3%。本季表現受美國麻醉與重症照護產品的強勁成長所帶動,主要來自 BREVIBLOC(速效靜脈注射 β 阻斷劑)與 Transderm SCOP 的銷售增加。由於 Transderm SCOP 的替代供應商回到市場的時間略晚於預期,我們本季也獲得些許正面助益。

  • Globally, BioSurgery sales slightly declined during the quarter. Mid-single-digit growth of [pore] hemostats and sealants was more than offset by the impact from lower sales of non-core products such as Peri-Strips and Actifuse.

    在全球範圍內,BioSurgery 銷售於本季小幅下滑。[pore] 止血材料與封合劑(hemostats and sealants)的中個位數成長,仍不足以抵銷 Peri-Strips 與 Actifuse 等非核心產品銷售下滑的影響。

  • Finally, in Hospital Products, sales in our other category were $110 million, declining 10%.

    最後,在醫院產品中,我們其他類別的銷售額為 1.10 億美元,下滑 10%。

  • Growth in the quarter was impacted by lower demand for our contract manufacturing services in our Bloomington, Indiana facility and lower manufacturing service revenues from Shire.

    本季成長受到印第安納州布盧明頓(Bloomington, Indiana)廠區合約製造服務需求下降,以及來自 Shire 的製造服務收入減少所影響。

  • Turning to our Renal business. Sales were $968 million, up 3% operationally. Sales in the quarter benefited from solid sales of peritoneal dialysis and acute renal care products.

    接著談腎臟(Renal)業務。銷售額為 9.68 億美元,營運基礎成長 3%。本季銷售受腹膜透析與急性腎臟照護產品穩健銷售所帶動。

  • The in-center hemodialysis business advanced low single digits globally, driven by strong sales in the U.S., partially offset by lower sales internationally.

    院內血液透析(in-center hemodialysis)業務在全球呈現低個位數成長,主要由美國強勁銷售帶動,但部分被國際市場較低的銷售所抵銷。

  • The acute business delivered mid-single-digit growth globally in the quarter, driven by increased sales internationally. Growth in the U.S. slowed in the quarter given the difficult year-over-year comparison, as sales in Q2 2016 benefited from a temporary market disruption for continuous renal replacement solutions. We expect growth in this business to return to double digits in the back half of the year.

    急性(acute)業務本季在全球實現中個位數成長,主要由國際銷售增加所驅動。由於去年同期比較基期較高,美國本季成長放緩;2016 年第二季的銷售曾受連續性腎臟替代治療(continuous renal replacement)溶液短期市場供應中斷而受惠。我們預期該業務在今年下半年將恢復至雙位數成長。

  • Walking through the rest of the P&L. Adjusted gross margin of 45.2% represents an improvement of 140 basis points over the prior year, driven by improved pricing in select areas of the portfolio, favorable manufacturing performance and a benefit from our business transformation efforts aimed at simplifying the portfolio to drive efficiency and reduce costs.

    接著說明損益表其餘項目。調整後毛利率為 45.2%,較去年提升 140 個基點,主要受產品組合部分領域的定價改善、有利的製造表現,以及我們業務轉型措施帶來的效益所驅動;該等措施旨在簡化產品組合以提升效率並降低成本。

  • Adjusted SG&A totaled $603 million, decreasing 9% on a reported basis. The primary driver of the improvement was our ongoing focus on effectively managing our expense base to eliminate costs and reduce inefficiencies.

    調整後銷售、一般及行政費用(SG&A)合計 6.03 億美元,以報告基礎計下降 9%。改善的主要驅動因素是我們持續聚焦有效管理費用基礎,以消除成本並降低低效率。

  • Transition service agreement total income totaled approximately $16 million in the quarter, a reduction of approximately $10 million compared to the second quarter of 2016. We expect transition service income to total approximately $20 million in the second half of 2017.

    本季過渡服務協議(Transition Service Agreement)總收入約 1,600 萬美元,較 2016 年第二季減少約 1,000 萬美元。我們預期 2017 年下半年過渡服務收入合計約 2,000 萬美元。

  • Adjusted R&D spending in the quarter of $155 million increased 3% versus the prior year. This reflects our stated intention to increase investments in R&D to drive innovation and augment top line growth.

    本季調整後研發(R&D)支出為 1.55 億美元,較去年增加 3%。這反映我們先前所述將增加研發投資,以推動創新並增強營收成長。

  • Adjusted operating margin in the quarter was 16.1%, an improvement of 380 basis points versus the prior year. Operating margin compared favorably to our expectations, driven by improved gross margin and disciplined expense management.

    本季調整後營業利益率為 16.1%,較去年提升 380 個基點。營業利益率優於我們的預期,主要受毛利率改善與嚴謹的費用管理所帶動。

  • Net interest expense was $13 million in the quarter, as was adjusted other income, which totaled $13 million in the quarter. This reflected a benefit from foreign exchange gains on balance sheet positions.

    本季淨利息費用為 1,300 萬美元;調整後其他收益亦為 1,300 萬美元。這反映了資產負債表部位因外匯收益所帶來的助益。

  • The adjusted tax rate was 16.9% for the quarter, which reflects a benefit from the new stock compensation guidance, along with select discrete items.

    本季調整後有效稅率為 16.9%,反映新股權薪酬指引帶來的效益,以及若干一次性項目。

  • And as previously mentioned, adjusted earnings of $0.63 per diluted share exceeded our guidance of $0.55 to $0.57 per share, driven by operational strength, other income benefit and a lower tax expense.

    如先前所提,調整後每股稀釋盈餘 0.63 美元高於我們每股 0.55 至 0.57 美元的指引,主要由營運動能、其他收益助益以及較低的稅負費用所驅動。

  • During the second quarter, we repurchased approximately $45 million or approximately 750,000 in shares. These targeted repurchases were more than offset by option-related dilution.

    第二季期間,我們回購約 4,500 萬美元、約 75 萬股的股票。這些具針對性的回購,仍被與選擇權相關的稀釋效應所抵銷。

  • Before turning to our updated outlook, I will provide some commentary regarding our cash flow performance. On a year-to-date basis, we've generated free cash flow of $488 million, an improvement of more than $400 million versus the prior year, driven by strong operational performance and lower capital expenditures, along with continued focus on improving the company's working capital performance.

    在談到我們更新後的展望之前,我先就現金流表現提供一些說明。以年初至今計算,我們已產生 4.88 億美元的自由現金流,較去年改善超過 4 億美元,主要受強勁的營運表現與較低的資本支出所帶動,同時也持續聚焦改善公司的營運資金表現。

  • Of particular note, we ended the quarter with DSO of 53 days and days payable of 52 days.

    特別值得注意的是,本季末我們的應收帳款週轉天數(DSO)為 53 天,應付帳款天數為 52 天。

  • Let me conclude my comments this morning by providing an update on our outlook for 2017 and 2020. Starting with 2017, we expect full year sales to increase approximately 3% on a reported basis and approximately 4% on a constant currency basis. And after adjusting for the U.S. cyclophosphamide impact, select strategic product exits and removing the benefit from the proposed Claris acquisition, we expect underlying operational growth of approximately 5%. All 3 of these sales ranges represent an increase from our prior guidance.

    最後,讓我在今天上午的發言結束前,更新我們對 2017 年與 2020 年的展望。先從 2017 年開始,我們預期全年銷售額以報告基礎計約成長 3%,以固定匯率基礎計約成長 4%。此外,在調整美國環磷醯胺(cyclophosphamide)的影響、部分策略性產品退出,以及剔除擬議中的 Claris 收購案所帶來的效益後,我們預期基礎營運成長約為 5%。上述三個銷售區間皆較我們先前的指引有所上調。

  • This growth reflects approximately $55 million in incremental sales from the Claris acquisition, which as Joe said, we expect to close imminently.

    此成長反映了來自 Claris 收購案約 5,500 萬美元的增量銷售額;如 Joe 所說,我們預期將在近期完成交割。

  • We now expect growth in the Hospital Products business of 4% to 5% on a constant-currency basis and 5% to 6% operationally.

    我們目前預期醫院產品(Hospital Products)業務以固定匯率基礎計成長 4% 至 5%,以營運基礎計成長 5% 至 6%。

  • Within Hospital Products, we now expect Fluid Systems constant currency sales growth of 5% to 6% and 7% to 8% on an operational basis.

    在醫院產品之中,我們目前預期輸液系統(Fluid Systems)以固定匯率基礎計銷售成長 5% 至 6%,以營運基礎計成長 7% 至 8%。

  • For the Integrated Pharmacy Solutions business, we expect constant currency sales growth of 4% to 5%. We expect full year sales for cyclophosphamide of approximately $160 million as compared to our previous guidance of $135 million. Our updated assumption is that additional competitors will enter the market during the fourth quarter of 2017.

    就整合藥房解決方案(Integrated Pharmacy Solutions, IPS)業務而言,我們預期以固定匯率基礎計銷售成長 4% 至 5%。我們預期全年環磷醯胺銷售額約為 1.6 億美元,高於先前指引的 1.35 億美元。我們更新後的假設是,將有更多競爭者在 2017 年第四季進入市場。

  • And as I just mentioned, we anticipate that Claris will add approximately $55 million of revenues to IPS.

    此外,如我剛才提到的,我們預期 Claris 將為 IPS 增加約 5,500 萬美元的營收。

  • Operationally, IPS sales are expected to increase 4% to 5%.

    以營運基礎計,IPS 銷售額預期將成長 4% 至 5%。

  • Within Surgical Care, we now anticipate sales to grow approximately 4% on a constant-currency basis and 4% to 5% operationally.

    在外科照護(Surgical Care)方面,我們目前預期銷售額以固定匯率基礎計約成長 4%,以營運基礎計成長 4% 至 5%。

  • And finally, for the Hospital Products business, we now expect bps and other to increase low single digits.

    最後,就醫院產品業務而言,我們目前預期 bps 與其他項目將以低個位數成長。

  • For the Renal business, we expect full year constant currency sales to increase approximately 3% and growth of approximately 4% operationally.

    在腎臟(Renal)業務方面,我們預期全年以固定匯率基礎計銷售額約成長 3%,以營運基礎計約成長 4%。

  • Moving down the P&L. We now expect an adjusted operating margin of approximately 15.5% to 16%.

    接著看損益表(P&L)。我們目前預期調整後營業利益率約為 15.5% 至 16%。

  • We expect net interest expense to total approximately $60 million and other income of approximately $20 million for 2017.

    我們預期 2017 年淨利息費用合計約 6,000 萬美元,其他收入約 2,000 萬美元。

  • For the year, we now expect an average adjusted tax rate of approximately 19.5%. For full year 2017, we anticipate a diluted average share count of approximately 555 million shares.

    就全年而言,我們目前預期平均調整後稅率約為 19.5%。2017 全年,我們預期稀釋後平均流通股數約為 5.55 億股。

  • Based on these factors, we now expect 2017 adjusted earnings, excluding special items, of $2.34 to $2.40 per diluted share.

    基於上述因素,我們目前預期 2017 年調整後盈餘(不含特殊項目)為每股稀釋後 2.34 至 2.40 美元。

  • Finally, for the year, we are increasing our outlook and now expect to generate operating cash flow of approximately $1.8 billion and free cash flow of approximately $1.1 billion.

    最後,就全年而言,我們上調展望,並預期產生約 18 億美元的營運現金流,以及約 11 億美元的自由現金流。

  • Specific to the third quarter of 2017, we expect sales growth to increase approximately 4% on a reported basis and increase approximately 5% on a constant-currency basis.

    針對 2017 年第三季,我們預期銷售成長以報告基礎計約增加 4%,以固定匯率基礎計約增加 5%。

  • Operationally, sales in the third quarter are expected to increase approximately 6%.

    以營運基礎計,第三季銷售額預期約成長 6%。

  • Claris is expected to contribute approximately $20 million in sales to the third quarter.

    Claris 預期將為第三季貢獻約 2,000 萬美元的銷售額。

  • And we expect adjusted earnings, excluding special items, of $0.58 to $0.60 per diluted share.

    我們預期調整後盈餘(不含特殊項目)為每股稀釋後 0.58 至 0.60 美元。

  • Before opening up the call to Q&A, I'd like to expand a bit on our updated longer-term financial outlook. Since we provided our updated projections last May, we've been very focused on opportunities for improvement. Our solid operational performance to date has positioned us well for continued success.

    在開放問答之前,我想再多談一些我們更新後的較長期財務展望。自從我們在去年 5 月提供更新後的預測以來,我們一直非常專注於改善機會。截至目前穩健的營運表現,使我們在持續成功方面具備良好定位。

  • As Joe stated, we expect sales growth of 4% compounded annually. While our sales outlook has not changed, I do want to point out a couple of factors. Top line performance in 2016 came in better than we had projected in May of 2016, and the guidance provided last year did not incorporate the select strategic exits we undertook this year. These 2 factors offset the expected benefit from the Claris acquisition.

    如 Joe 所述,我們預期銷售成長以年複合成長率 4% 成長。雖然我們的銷售展望並未改變,但我確實想指出幾個因素。2016 年的營收表現優於我們在 2016 年 5 月所做的預測,而去年提供的指引並未納入我們今年所進行的部分策略性退出。這兩項因素抵銷了預期來自 Claris 收購案的效益。

  • In addition, as we approach 2020, we expect sales growth to be north of 4% on an annual basis, as we benefit from the actions we've taken to optimize the portfolio and drive increased productivity from our pipeline investments.

    此外,隨著我們接近 2020 年,我們預期年度銷售成長將高於 4%,因為我們將受惠於已採取的行動以優化產品組合,並從我們對產品線(pipeline)投資中推動更高的生產力。

  • The adjusted operating margin of 20% compares favorably to previous guidance of 17% to 18% and reflects continued momentum from our business transformation efforts as well as improved manufacturing performance.

    調整後營業利益率 20% 相較於先前 17% 至 18% 的指引更具優勢,並反映我們業務轉型努力的持續動能,以及製造表現的改善。

  • In 2020, we expect adjusted EPS of $3.25 to $3.40 per share, representing a mid-teens increase from the prior guidance of $2.75 to $3.00 per share. Our EPS outlook does not assume any meaningful share repurchases. We've only modeled repurchases to offset dilution, holding our share count flat to 2017 levels.

    在 2020 年,我們預期調整後每股盈餘(EPS)為每股 3.25 至 3.40 美元,較先前每股 2.75 至 3.00 美元的指引呈現約中十位數百分比的提升。我們的 EPS 展望並未假設任何具實質規模的庫藏股回購。我們僅將回購納入模型以抵銷稀釋,並使股數維持在 2017 年水準不變。

  • In addition, we've not included any additional meaningful business development initiatives beyond the Claris acquisition in these projections.

    此外,在這些預測中,除 Claris 收購案外,我們未納入任何額外具實質規模的業務開發(business development)計畫。

  • For me, one of the most important numbers Joe mentioned earlier is our increased cash flow outlook. We expect to generate more than $2.6 billion in operating cash flow by 2020. We will further reduce CapEx spending, which is expected to be less than 6% of sales by 2020, resulting in free cash flow improving approximately $250 million to approximately $2 billion in 2020.

    對我而言,Joe 先前提到最重要的數字之一,是我們上調的現金流展望。我們預期到 2020 年將產生超過 26 億美元的營運現金流。我們將進一步降低資本支出(CapEx),預期到 2020 年將低於銷售額的 6%,使自由現金流改善約 2.5 億美元,並在 2020 年達到約 20 億美元。

  • And to rephrase my earlier comment, this is an unlevered view of our business. It does not reflect any meaningful deployment of the balance sheet other than the repurchase of shares to offset dilution.

    換句話說,呼應我先前的評論,這是對我們業務的無槓桿(unlevered)觀點。除為抵銷稀釋而回購股份外,並未反映任何其他具實質規模的資產負債表運用。

  • Similar to our previous guidance, this plan was built from the bottoms up. We're pleased with this update. But as always, we'll look for ways to enhance this performance. And 2020, by no means, represents the peak, but rather just another step in our journey.

    與我們先前的指引類似,這項計畫是自下而上建立的。我們對此次更新感到滿意。但一如既往,我們仍會尋找方法以進一步提升表現。而 2020 年絕非高峰,而只是我們旅程中的另一個里程碑。

  • We expect to host an Investor Day during the second quarter of 2018, where we will provide a review of our business strategies, product pipeline, innovation, along with a more extended financial outlook.

    我們預期將於 2018 年第二季舉辦投資人日(Investor Day),屆時將回顧我們的業務策略、產品線(pipeline)、創新,以及更延伸的財務展望。

  • With that, we can now open up the call for Q&A.

    接下來,我們可以開放問答。

  • Operator

    Operator

  • (Operator Instructions) I would like to remind everyone that the call is being recorded, and the digital replay will be available on the Baxter International's website for 60 days at www.baxter.com. And our first question comes from Vijay Kumar of Evercore ISI.

    (接線員指示)提醒各位,本次電話會議將被錄音,並且數位重播將於 Baxter International 的網站提供 60 天,網址為 www.baxter.com。第一個問題來自 Evercore ISI 的 Vijay Kumar。

  • Vijay Muniyappa Kumar - MD and Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD and Fundamental Research Analyst

  • So maybe up, one on the LRP. And I'm curious, the revenue outlook of 4%, that wasn't changed. I mean, just given the underlying momentum we're seeing in the business, I'm curious why that was maintained. And does the LRP contemplate any increase in gross margins?

    我想先問一個關於長期計畫(LRP)的问题。我很好奇,4% 的營收展望並沒有改變。考量到我們在業務中看到的基礎動能,我想知道為什麼仍維持這個數字。另外,LRP 是否有納入毛利率提升?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Sure, Vijay. Thanks for the question.

    當然可以,Vijay。謝謝你的提問。

  • So just commenting on your second question first with respect to gross margin performance over the LRP. In the last -- in last year's iteration of our financial projections, we shared an operating margin of roughly 17% to 18%. We've increased that to 20% in our current look at 2020. But to decompose the 17% to 18%, we were really in the range of 44% to 45% on a gross margin standpoint. R&D was roughly 5%, and then SG&A was 22%. As we move to this year's LRP, there are a number of areas of improvement. One of the biggest relates to gross margin, where we now expect roughly a 46% gross margin in 2020.

    先就您第二個問題、也就是在 LRP 期間毛利率表現的部分做個說明。在去年那一版的財務預測中,我們分享的營業利益率大約是 17% 到 18%。在目前對 2020 年的最新檢視中,我們已將其提高到 20%。但若拆解當時的 17% 到 18%,以毛利率角度來看,我們大約落在 44% 到 45% 的區間。研發約為 5%,而 SG&A 約為 22%。隨著我們進入今年的 LRP,有多個面向出現改善。其中最大的一項與毛利率相關,我們現在預期 2020 年毛利率約為 46%。

  • There are a number of contributing factors to this. I said in the past, I've been very pleased with the manufacturing performance under the leadership of Scott Pleau. That team has been incredibly focused on driving cost savings and improvements in the manufacturing network. So we expect to see some of that. But on the gross margin line, we'll also benefit from mix as we move forward, as we did exit some lower-margin sales; and then furthermore, as we look at the inclusion of Claris in our projections.

    這背後有多項促成因素。我過去也提過,在 Scott Pleau 的領導下,我對製造端的表現非常滿意。該團隊極度專注於推動成本節省以及製造網路的改善。因此我們預期會看到其中一部分效益。但在毛利率這一行,我們也會因為產品組合(mix)而受益;因為我們確實退出了一些較低毛利的銷售;此外,當我們把 Claris 納入預測時,也會帶來進一步的影響。

  • To complete the picture, R&D is basically unchanged versus the prior iteration, and SG&A improves another 100 basis points, again driven by continued and relentless focus on cost. So that's really the picture from a margin standpoint.

    為了把整體圖像補齊,研發相較於前一版基本上沒有變化,而 SG&A 再改善 100 個基點,同樣是由持續且不懈的成本聚焦所驅動。所以從利潤率角度來看,大致就是這樣的情況。

  • As it relates to sales projections, yes, I think it's safe to say we've been very pleased with the sales performance of our business, right? And as we look at the LRP, really the biggest changes for us are a couple of fold. One, we've included Claris. So the IPS business now will grow faster than we previously expected, but then we did exit certain strategic lower-margin sales areas. And so we do have an impact on Fluid Systems and on the Renal business. Those business growths are down a little bit from the prior version of the LRP.

    至於銷售預測,是的,我想可以很有把握地說,我們對業務的銷售表現一直非常滿意,對吧?而在檢視 LRP 時,對我們而言最大的變動主要有幾個面向。第一,我們把 Claris 納入了。因此 IPS 業務現在的成長會比我們先前預期更快,但同時我們也退出了某些策略性但低毛利的銷售領域。所以這會對 Fluid Systems 以及 Renal 業務造成影響。這些業務的成長率相較於前一版 LRP 會略低一些。

  • So as we sit here today, obviously we're looking to accelerate wherever possible. And in fact, Joe's comments and my comments around innovation, as we look over long term, we're looking to accelerate the pace of innovation and pull forward where possible. But as we sit here today, we feel comfortable with the 4%.

    因此以我們今天所處的位置來看,顯然我們希望在任何可能之處加速。事實上,Joe 的評論以及我的評論都提到創新;從長期來看,我們希望加快創新的步伐,並在可能的情況下把時程往前拉。但就目前而言,我們對 4% 這個數字感到有信心。

  • Vijay Muniyappa Kumar - MD and Fundamental Research Analyst

    Vijay Muniyappa Kumar - MD and Fundamental Research Analyst

  • Absolutely. And then, just one follow-up, guys, on just maybe the guidance for the current fiscal. You look at the one half versus second half mix, the last couple of years, it's somewhere in 40%, 45% in one half versus 55% to 60% in second half. I know you have a number of items hitting you in the back half, including the PSA transition. The guidance basically implies the mix is more 50-50 this year. Can you just walk us through that, Jay?

    完全同意。另外再追問一個問題,各位,關於本會計年度的指引。你看過去幾年上半年對下半年的比重,上半年大概在 40% 到 45%,下半年則在 55% 到 60%。我知道下半年有不少事項會影響你們,包括 PSA 轉換。但這次的指引基本上暗示今年的比重更接近 50-50。Jay,你能帶我們走一遍其中的原因嗎?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Certainly. We would normally expect to see an uptick in the second-half EPS just based on natural business trends, and that's something that we've seen over the last several years.

    當然可以。我們通常會預期下半年 EPS 會上升,主要是基於自然的業務趨勢,而這也是我們過去幾年所看到的情況。

  • There are several factors that we have to be mindful of. First of all, transition service income. We expect Shire to wind down their need for our services. And right now, that's a $0.03 headwind, first half to second half.

    有幾個因素我們必須留意。首先是過渡服務收入(transition service income)。我們預期 Shire 對我們服務的需求會逐步降低。而目前這在上半年到下半年之間帶來 $0.03 的逆風。

  • Secondly, we did -- from a cyclo performance standpoint, we have roughly $0.04 of deterioration -- $0.03 to $0.04 of deterioration, first half to second half. Third, we are going to be accelerating some R&D investments. I think these are very strategic and important. And as we get to your first question in relation to how do we accelerate sales growth, it's very much about pulling forward timelines as much as possible, something our team is really focused on. R&D ticks up roughly $0.03 in the second half of the year.

    第二,從 cyclo 表現的角度來看,我們大約有 $0.04 的惡化——上半年到下半年約 $0.03 到 $0.04 的惡化。第三,我們將加速部分研發投資。我認為這些都非常具策略性且重要。而回到你第一個問題、也就是我們如何加速銷售成長,這很大程度上就是盡可能把時程往前拉,這也是我們團隊非常專注的事情。研發在下半年大約增加 $0.03。

  • And then finally, the way the tax rate works with the benefits related to FAS 123R, typically, those benefits are concentrated in the first half of the year. And so we do see the tax rate ticking up $0.03 to $0.04. And finally, we have other income and interest, which is $0.01 -- or there's a $0.01 impact in the second half of the year. So as we look at the first half to the second half, there are roughly $0.14 to $0.15 of headwinds, as we analyze it, that we fight through to give the guidance that we've shared with you today.

    最後,稅率的運作方式與 FAS 123R 相關的稅務利益有關;通常這些利益集中在上半年。因此我們確實看到稅率上升,影響約 $0.03 到 $0.04。另外,我們還有其他收入與利息,在下半年有 $0.01 的影響——也就是下半年有 $0.01 的影響。所以當我們分析上半年到下半年時,大約有 $0.14 到 $0.15 的逆風需要克服,才能給出我們今天與各位分享的指引。

  • Operator

    Operator

  • And our next question comes from Mike Weinstein of JPMorgan.

    下一個問題來自 JPMorgan 的 Mike Weinstein。

  • Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

    Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

  • Maybe I can sneak in 2 questions here. So one, can you talk about the Claris accretion to your 2020 guidance with what the expected EPS contribution would be? And then second, I just want to make sure I'm reading the capital allocation slide correctly on the dividend. So is the assumption that the dividend payout ratio is still 35% or something below that?

    也許我可以在這裡插入兩個問題。第一,你能談談 Claris 對你們 2020 年指引的增厚(accretion)效果,以及預期的 EPS 貢獻會是多少嗎?第二,我想確認我是否正確解讀資本配置投影片中關於股利的部分。所以假設仍是股利支付率 35%,或是低於這個水準?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes. From a Claris standpoint, we expect roughly $0.05 of accretion in 2020, a little bit north of that. And then from a dividend payout ratio, our expectation is to maintain, over the long term, this targeted payout ratio of 35% of adjusted net income. As you know...

    是的。就 Claris 而言,我們預期 2020 年大約有 $0.05 的增厚效果,會略高於這個數字。至於股利支付率,我們的預期是在長期維持這個目標支付率,也就是調整後淨利的 35%。如你所知……

  • Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

    Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

  • And then, Joe, we just want to get your kind of latest thoughts on business development. On the last quarter call, we talked about the potential for larger acquisitions. And then it felt, I think, to The Street as if the likelihood of larger transactions may be diminished over the course of the quarter. So can you just give us your latest read on kind of what's out there? And what's the likelihood of different sizes occurring?

    另外,Joe,我們也想聽聽你對業務開發(business development)最新的看法。在上一季的電話會議上,我們談到較大型併購的可能性。但我覺得,市場(The Street)似乎感覺在這一季期間,較大型交易發生的可能性可能降低了。所以你能否分享你對目前外部機會的最新判讀?以及不同規模交易發生的可能性如何?

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • Sure, Mike. Just augmenting Jay's previous answer on Claris, we're giving this guidance on Claris for 2020. As Claris is to-date, Claris for Baxter is the foundation of getting us to a significant number of molecules in other areas. So when we speak about Claris itself, as Claris as it is today, is it transitions over there, there's a significant amount of investment that we're going to be making in new molecules, that will be adding to the pharmaceutical business of Baxter, which we plan to be much bigger than just Claris.

    當然可以,Mike。先補充 Jay 先前對 Claris 的回答,我們提供的是 Claris 在 2020 年的這份指引。就目前為止,對 Baxter 而言,Claris 是讓我們在其他領域取得大量分子(molecules)的基礎。因此當我們談 Claris 本身、也就是 Claris 目前的樣貌、以及它在那邊的轉換時,我們將在新分子上投入相當多的投資,這些將會為 Baxter 的製藥業務帶來增量,而我們規劃的規模會遠大於僅僅是 Claris。

  • On the business development, we have a significant capacity in our balance sheet, organic and inorganic, meaning we are generating a significant amount of cash. I think Jay has spoken about our conversion ratio as really good. It's one of the best I've seen. The team has done a great job. So our natural generation of cash, plus what we can borrow, put us in a very good position. So what is the difference between where I am right now and a big acquisition and several tuck-ins that we'll get to the value that we had spoken last quarter, but in a different way?

    在業務開發方面,我們的資產負債表有相當大的容量,包含有機與無機,也就是說我們正在產生大量現金。我想 Jay 也談過我們的轉換率非常好。這是我見過最好的之一。團隊做得非常出色。因此,我們自然產生的現金,加上我們可以舉借的資金,讓我們處於非常有利的位置。所以,我現在所處的位置,與進行一筆大型收購、或是透過幾個補強型收購(tuck-ins)來達到我們上季所談的價值之間,差別是什麼——只是用不同的方式來實現而已?

  • Clearly, there is scarcity of large targets, as we all know, so -- and also, when you look into the financials and how that works with the company, you have an inherited risk pertinence to these kinds of transactions. They're much greater than several smaller transactions. So as we look at how to pursue our inorganic pathway here, first of all, put a strong team in place. And I just brought my old team back, almost the whole team back from my old job into Baxter. And that team will be now responsible for M&A.

    顯然,正如大家所知,大型標的相當稀缺;而且,當你深入檢視財務狀況以及其與公司運作方式的關聯時,這類交易本身就帶有固有的風險相關性。這些風險遠高於數筆較小的交易。因此,當我們思考在此推進非有機成長路徑時,首先要建立一支強而有力的團隊。我剛把我以前的團隊幾乎整個都從上一份工作帶回來加入 Baxter。而這個團隊現在將負責併購(M&A)。

  • The second thing is that, for me, it doesn't matter. If you do a large deal, it's going to take us a while to digest, and will probably take us a while to continue down the path of further acquisitions versus these smaller deals. So as we evaluate both, we have -- we're open for both. It's not that one is losing to the other, it's what are the opportunities that we'll return to our shareholders what we want the shareholders to have.

    第二點是,對我而言,其實無所謂。如果你做一筆大型交易,我們需要一段時間去消化,且相較於這些較小的交易,我們可能也需要一段時間才能繼續走向後續收購的道路。因此,在評估兩者時,我們——我們對兩者都保持開放。不是說其中一個輸給另一個,而是看有哪些機會能讓我們回饋股東、達到我們希望股東獲得的回報。

  • Remember, we want internal rate of returns that are significant above our weighted average cost of capital, in the double digits. We want ROIC 3 to 5 years to have now close to the company average. So we have put some limits in how we're going to use our shareholders' money. The other alternative that we have, we have said that money is not going to burn a hole in our pocket. So if we do have excess cash, we will buy shares back at our discretion, when we think it's the most effective way of doing so.

    請記得,我們希望內部報酬率(IRR)顯著高於加權平均資本成本(WACC),也就是達到兩位數。我們希望投資資本報酬率(ROIC)在 3 到 5 年內接近公司的平均水準。因此,我們對如何使用股東資金設下了一些限制。我們的另一個選項是,我們已經說過,這筆錢不會在口袋裡燒出洞來。所以如果我們確實有多餘現金,我們會在我們認為最有效的時點,酌情進行庫藏股回購。

  • We're opening both channels. And we can do both at the same time, because of the amount of cash that we have. So as we pursue diligently and with significant amount of grit, our M&A path, we also will be returning money to the shareholders in terms of shares buyback. So I want to leave those channels open. And size of acquisition is less important than the strategic fit of those companies within our portfolio.

    我們同時開放兩個管道。而且基於我們手上的現金規模,我們可以同時進行兩者。因此,在我們以高度紀律與相當的韌性積極推進併購路徑的同時,我們也會透過股票回購把資金回饋給股東。所以我希望這些管道都保持開放。而收購的規模不如這些公司與我們投資組合的策略契合度來得重要。

  • Operator

    Operator

  • And our next question comes from Matthew Taylor of Barclays.

    下一個問題來自 Barclays 的 Matthew Taylor。

  • Matthew Charles Taylor - Director

    Matthew Charles Taylor - Director

  • So I wanted to follow up on some of the thoughts on the Claris accretion, and maybe just spin this into a discussion around how you think the mix could improve with your injectable initiatives in general. Could you give us some thoughts on the different partnerships that you have, Claris and in your internal programs? And what you think the margin structure of that business could look like over the course of the LRP? Because as you know, not all injectable businesses are created equal.

    我想延伸追問一下關於 Claris 增厚(accretion)的一些看法,並且也許把這點延伸成一個討論:你如何看待整體注射劑相關計畫,產品組合結構(mix)可能如何改善。你能否談談你們不同的合作夥伴關係,包括 Claris 以及你們內部計畫?以及在 LRP 期間,你認為該業務的毛利結構可能會是什麼樣子?因為如你所知,不是所有注射劑業務都一樣。

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • Yes. We feel that we have 3 pathways here. We had our internal programs, which I thought were good, but not at all sufficient. Those were good molecules. Our internal program, when we first arrived at Baxter, were related to things that are difficult to create a solution to stabilize. We're looking at our GALAXY technology in Round Lake, Illinois to make them, and our pace was one of not great speed, okay? So that program could only -- would not get us where we want.

    是的。我們認為這裡有三條路徑。我們有內部計畫,我覺得不錯,但完全不夠。那些是好的分子。我們剛到 Baxter 時的內部計畫,主要與一些很難做出穩定化解決方案的項目相關。我們在伊利諾州 Round Lake 以 GALAXY 技術來製造它們,而我們的進度並不快,好嗎?所以那個計畫只能——無法帶我們到達我們想去的地方。

  • Claris adds a piece of the puzzle, which is the ability to do the filling operations and packaging, also the procurement of APIs -- the manufacturing of APIs in a very cost-effective way with good quality product.

    Claris 補上了拼圖中的一塊,也就是具備充填作業與包裝的能力,同時也能採購 API(活性藥物成分)——並以非常具成本效益的方式製造 API,且產品品質良好。

  • We are expanding now with the ScinoPharm and as well as the result of partnerships to be able to get more volume of molecules. But this is not volume of $1 million molecules. We're looking at molecules that are more relevant to the portfolio, therefore creating good accretion to the gross margin.

    我們現在透過擴展與 ScinoPharm 的合作,以及其他合作夥伴關係的成果,來取得更多分子的產能/供給量。但這不是那種只有 100 萬美元規模的分子量。我們鎖定的是與投資組合更相關的分子,因此能對毛利率帶來良好的增厚。

  • If you think about this business, this is a business with a low SG&A. So it's all about gross margin here. And gross margins is providing the market with effective supply chain that creates a cost advantage for us in the market and for the customer. So with 45%, and Jay said 46% by 2020, we feel this business has a bigger capacity to deliver on the gross margin, but more so, Matt, is down the P&L with very low SG&A, okay?

    如果你思考這門業務,這是一個 SG&A(銷售、一般及行政費用)很低的業務。所以重點完全在毛利率。而毛利率來自於提供市場一個有效的供應鏈,為我們在市場上以及為客戶創造成本優勢。因此,以 45%(Jay 說到 2020 年是 46%)來看,我們認為這門業務在毛利率上有更大的提升空間;但更重要的是,Matt,在損益表(P&L)往下看,SG&A 非常低,好嗎?

  • So we are actively, actively pursuing more partnerships and with all kinds of different companies either for distribution of the drug, for augmentation of portfolio, for the design of this generics, which is the case of hard-to-make oncolytics with ScinoPharm, or just capacity to develop the API and the formulation with Dorizoe. So it's all in a -- when you put together, it is a business -- it's a core growth business for us, which is the definition is, has better gross margin, better growth rates, change to vector of growth and also impacts our operating income and our EPS.

    因此,我們正非常、非常積極地追求更多合作夥伴關係,與各種不同公司合作:不論是藥品的通路/配銷、投資組合的擴充、這些學名藥的設計(例如與 ScinoPharm 合作的難製作腫瘤用藥),或是像與 Dorizoe 合作,取得開發 API 與配方的能力。所以把這些整合起來,這是一門——對我們而言是核心成長業務;其定義是:更高的毛利率、更高的成長率、改變成長向量,並且也會影響我們的營業利益與每股盈餘(EPS)。

  • Matthew Charles Taylor - Director

    Matthew Charles Taylor - Director

  • Some helpful perspective. And I just wanted to follow up on the Fluid Systems business. That continues to perform very well. I know you've been saying it kind of gets the trophy every quarter for best performing business. And I just wanted to understand some of the dynamics there between, I guess, the competitive environment and share gains, how you're doing on pricing and some of the pull-through. Maybe you could touch on those things to understand how much longer you can continue to grow above-market like this.

    這些觀點很有幫助。我也想追問一下 Fluid Systems(輸液系統)業務。它持續表現非常好。我知道你們一直說它幾乎每一季都拿到「最佳表現業務」的獎盃。我想了解其中的一些動態:我猜包括競爭環境與市占提升、你們在定價上的表現,以及一些帶動效應(pull-through)。也許你可以談談這些,幫助我們理解你們還能在多長時間內像這樣持續跑贏市場成長。

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • Well, if you think about the fluids business in general, we came back to the market with an effective pump strategy. We have probably 22%, 22.5%, 23% market share in pumps, and where we are today, and I'm talking about the U.S. per se. So let's focus on the U.S., as the Fluids business outside the U.S. has completely different characteristics and profit profile.

    嗯,如果你從整體輸液業務來看,我們以一個有效的幫浦策略重新回到市場。我們在幫浦的市占大概是 22%、22.5%、23%,以我們目前的位置來看——我指的是美國市場本身。所以我們先聚焦美國,因為美國以外的輸液業務具有完全不同的特性與獲利結構。

  • So the pumps in the U.S. is the SIGMA SPECTRUM. We have a nice momentum on product development. We're going to be launching the new revised version of SIGMA with our programmable functions and other features next year. And then we have a pathway all the way to a new platform not too far in the future. That is the foundation of creating momentum in terms of our fluids business.

    所以在美國的幫浦是 SIGMA SPECTRUM。我們在產品開發上有不錯的動能。我們將在明年推出新版 SIGMA,具備可程式化功能與其他特性。接著我們也有一條路徑,在不久的將來一路走向一個全新平台。這就是為我們輸液業務創造動能的基礎。

  • The fluids themselves is all about capacity and quality. And right now, I feel confident that we're working very hard in both fronts. So we have product availability as much as we can. We're augmenting capacity. We're validating new lines in our North America planned footprint. So the ability to provide product to the market at a higher rate is one that will determine in the future our ability to continue to grow.

    至於輸液本身,關鍵在於產能與品質。而目前我有信心,我們在這兩個面向都非常努力。因此,我們盡可能確保產品供應可得性。我們正在擴增產能。我們正在驗證北美規劃版圖中的新產線。因此,未來能以更高的速度向市場供貨的能力,將決定我們能否持續成長。

  • Remember, those products are not sold in the spot market. Those are created through contracts, and those are long-term contracts. So as long as Baxter has the capability to continue to provide those long-term contracts, where price escalation's built in. Second, we have invested in the right capacity, meaning when I say right capacity, it's capacity in the right places, and we are. And we maintain the quality required by the FDA. We will be -- continue to deliver on this business.

    請記得,這些產品不是在現貨市場銷售的。它們是透過合約來建立的,而且是長期合約。因此,只要 Baxter 有能力持續提供這些長期合約——其中已內建價格調升(price escalation)。第二,我們已投資在正確的產能;我所謂正確的產能,是指在正確的地點的產能,而我們確實如此。並且我們維持 FDA 所要求的品質。我們將會——持續在這項業務上交出成果。

  • Clearly, there is a point where there is a reduction in growth just by the sheer volume of products that we make. We're #1 in the market in terms of solutions. So we expect this business to taper off a little bit in growth, but our expectation is, as we continue to augment capacity, we continue to gain market share. And I think this is something that our team here in North America is doing a significant amount of work and will continue on to be able to provide products to our customers.

    顯然,僅僅因為我們生產的產品量非常龐大,成長在某個點上就會出現放緩。就解決方案而言,我們在市場上排名第 1。因此,我們預期這項業務的成長會稍微趨緩,但我們的預期是,隨著我們持續擴增產能,我們將持續提升市占率。我認為這也是我們北美團隊正在投入大量工作、並將持續推進的事項,以便能夠為客戶提供產品。

  • Operator

    Operator

  • And our next question comes from Larry Biegelsen of Wells Fargo.

    下一個問題來自富國銀行(Wells Fargo)的 Larry Biegelsen。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • Let me start with the 2020 margin -- operating margin target. Could you talk about how you thought about that target in 2020? Is there some conservatism baked in? Is there room for further expansion beyond the 20% in 2020 -- beyond 2020, I'm talking about? And how should we think about the path to 20%? Should we think about it linear between 2017 and 2020? And I did have one follow-up.

    我先從 2020 年的利潤率——營業利潤率目標談起。你能談談你們在 2020 年是如何思考這個目標的嗎?其中是否包含一些保守性?在 2020 年達到 20% 之後——我是指 2020 年之後——是否還有進一步擴張的空間?我們應該如何看待通往 20% 的路徑?我們是否應該把它視為 2017 年到 2020 年之間的線性變化?另外我還有一個追問。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Okay. Larry, thanks for the question.

    好的。Larry,謝謝你的提問。

  • Overall, from a margin standpoint, the first comment I would make is, we do not believe that 20% is the peak. In fact, as we share our guidance in May of next year, we'll extend beyond 2020. And you heard Joe make some earlier comments about businesses like our injectables business. There's incredible excitement around that, in part because of the higher margin those businesses carry than the Baxter corporate average. So as we move from 2020 to beyond, we start to get lift from mix and innovation, really, really accelerating and helping the margin improvement.

    整體而言,從利潤率的角度,我首先要說的是,我們不認為 20% 是峰值。事實上,當我們在明年 5 月分享指引時,我們會把展望延伸到 2020 年之後。你也聽到 Joe 先前對我們的注射劑業務等業務做了一些評論。我們對此非常振奮,其中一部分原因是,這些業務的利潤率高於 Baxter 的公司平均水準。因此,當我們從 2020 年走向更往後的期間時,我們將開始受惠於產品組合與創新帶來的拉抬,這將真正、非常快速地加速並推動利潤率改善。

  • In terms of how we develop the target, is it conservative or not, it's the same methodology that we've used over the last 3 years for developing our long-range financial planning commitments. Specifically, we have programs earmarked from a bottoms-up standpoint that sum totaled to 20%. In the past, I've talked with investors about outside-in and comparing to competitors and using that as a basis. But for us, we've never done that. We've always done bottoms-up initiative-by-initiative. And so we know exactly how we are going to get from where we are today, 15.5% to 16%, to the 2020 target of 20%. And in fact, as we leave this call, Joe and I will be going to a zero-based budgeting meeting, where we'll be reviewing many of the savings initiatives that support this 2020 objective.

    至於我們如何制定這個目標、它是否保守,方法論與我們過去 3 年用來制定長期財務規劃承諾的方式相同。具體而言,我們以自下而上的方式規劃了各項專案,這些專案加總起來對應到 20%。過去我曾與投資人談到由外而內、與競爭對手比較並以此作為基礎。但對我們而言,我們從未那樣做。我們一向是以自下而上、逐項倡議(initiative-by-initiative)的方式來做。因此,我們非常清楚要如何從目前的 15.5% 到 16%,走到 2020 年 20% 的目標。事實上,結束這通電話後,Joe 和我將去參加一場零基預算(zero-based budgeting)會議,屆時我們會檢視許多支持 2020 年目標的節省成本倡議。

  • As far as the linearity of this, I don't want to get into guidance discussions for 2018 at this point. What I will tell you is, it is not like there's 300 basis points of an improvement in a particular year. It is fairly balanced. But again, I'll stop short of giving annual targets for margin improvement.

    至於這個過程是否線性,我現在不想就 2018 年的指引進行討論。我能告訴你的是,並不是某一年就改善 300 個基點。整體而言相當均衡。但同樣地,我不會進一步提供每年的利潤率改善目標。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • That was, I guess, on the guidance. My follow-up question was just on the 4% CAGR. What's the -- on this revenue. What's the definition of that? It includes Claris, but it doesn't include other business development. And I did hear you say, Jay, that you expect -- or it may have been Joe, accelerating above 4% as you come to 2020. My question was going to be around how to think about 2018. Anything different from 2017? Should we be thinking about it in a similar way? Not sure if you're willing to kind of give us some of the puts and takes at this point.

    那是——我想——關於指引的部分。我的追問是關於 4% 的年複合成長率(CAGR)。這個——就營收而言——它的定義是什麼?它包含 Claris,但不包含其他業務開發。而且我確實聽到你說,Jay——或可能是 Joe——你們預期在接近 2020 年時會加速到高於 4%。我的問題是該如何看待 2018 年。和 2017 年相比有什麼不同嗎?我們是否應該用類似的方式來看待?不確定你們是否願意在此時給我們一些利多與利空因素(puts and takes)。

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • Larry, the way we think about the top line is the following.

    Larry,我們對營收端(top line)的看法如下。

  • Our weighted average market growth rate, our WAMGR, is about 3%, okay? So we have a 4% plan, which is significant amount of new product launches, geographic expansion, things you put an end to grow above market, primarily in our growth categories, okay, as we outlined in our presentations in the past, we call core growth.

    我們的加權平均市場成長率(WAMGR)大約是 3%,好嗎?因此我們的計畫是 4%,這需要相當多的新產品上市、地理擴張,以及你所提到的、讓我們能夠高於市場成長的各項作為,主要是在我們的成長類別中;正如我們過去簡報所概述的,我們稱之為核心成長(core growth)。

  • When you look at how to get to 5% is basically execution excellence on those initiatives and derisking those initiatives. So the more we derisk our initiatives, the more we fill our bullpen of new opportunities. We can possibly get to 5%. It's a stretch. It's not easy, and I'm not saying we're going to get there, but we have a lot of Baxter people probably listening to this call. We are getting ready to get there, because we're executing. We're doing everything we can.

    當你看要如何達到 5%,基本上就是在這些倡議上做到卓越執行,並降低這些倡議的風險(derisking)。因此,我們越能降低倡議風險、越能把新的機會填滿我們的「牛棚」(bullpen)。我們就有可能達到 5%。這是個拉伸目標。這並不容易,我也不是說我們一定會達到,但可能有很多 Baxter 的同仁正在收聽這通電話。我們正準備朝那個方向前進,因為我們正在執行。我們正在盡一切努力。

  • We brought good people from the outside, with excellent people from inside. We're mixing our teams with very good execution people. So we have a possibility to get there. But right now, we feel that with what we have on the table, 4% is adequate for our shareholders to model our growth going forward, but we are working hard to get to 5%.

    我們從外部引進了優秀的人才,也結合了內部的優秀人才。我們正在把團隊混編,加入非常擅長執行的人。因此我們有機會達成。但就目前而言,我們認為以我們現有的規劃,4% 足以讓股東用來建模我們未來的成長,但我們正努力朝 5% 邁進。

  • Operator

    Operator

  • And our next question comes from David Lewis of Morgan Stanley.

    下一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Just two questions, one short and one longer term. Jay, maybe you for the short-term question. If I think about the second quarter and back half of the year from an organic growth perspective, so momentum slowed a little bit in the second quarter, but your guidance implies a fairly material acceleration in organic growth into the third quarter. And then you have the easy comp in the fourth quarter. So I think about the 5% guidance at the top end, it looks like if you can do the third quarter, frankly, you would more than do that in the fourth quarter. So can you just help us understand the acceleration into the third quarter, and how you think the third quarter will play out in terms of your back half of the year growth guidance?

    我有兩個問題,一個短期、一個較長期。Jay,短期問題可能請你回答。如果我從有機成長的角度來看第二季以及下半年,第二季的動能稍微放緩,但你們的指引暗示第三季的有機成長將相當明顯地加速。而且第四季還有較容易的比較基期。所以我看你們上緣 5% 的指引,似乎如果第三季能做到,坦白說第四季就會更容易超過。因此你能否協助我們理解第三季的加速,以及你們認為第三季在下半年成長指引中會如何表現?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Sure. One important point relates to Claris. And so as we think about the growth rate for the third quarter, there is some benefit from Claris, roughly $15 million, in the third quarter -- or actually, is it $15 million or $20 million...

    當然。有一個重要點與 Claris 有關。因此當我們思考第三季的成長率時,Claris 會帶來一些助益,第三季大約 1,500 萬美元——或者其實是 1,500 萬還是 2,000 萬……

  • Clare Trachtman - Vice-President of Investor Relations

    Clare Trachtman - Vice-President of Investor Relations

  • $20 million...

    2,000 萬美元……

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • $20 million, sorry. $20 million in the third quarter. So that's one item.

    2,000 萬美元,抱歉。第三季是 2,000 萬美元。所以這是一個因素。

  • As far as other areas, there is some acceleration outside the U.S. And part of the business outside the U.S. relates to tenders. And so as we look at some of our regions, our CEMEA region, our Asia Pacific region, we do see a sequential growth from Q2 to Q3 based on the timing of tenders, which is a little bit different than we've seen in prior quarters and years. So really, that is one of the factors that drives this acceleration into the third quarter. And then, of course, we had a solid Q4 last year. So that factors into our math.

    至於其他領域,美國以外地區會有一些加速。而美國以外的部分業務與標案(tenders)有關。因此,當我們觀察某些區域,例如我們的 CEMEA 區域、亞太區域,我們確實看到因標案時點的關係,從第二季到第三季出現序列成長(sequential growth),這與我們在過去幾季與幾年所看到的情況略有不同。所以,這確實是推動第三季加速的因素之一。然後,當然,我們去年第四季表現也很強勁。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Okay, that's helpful. But can you sustain those levels, sorry, Jay, into the fourth quarter? Because then the comp gets a little easier. But is this -- it just feels like whatever you deliver in the third quarter should be able to do consistent growth in the fourth quarter, just based on the easier comparable.

    好的,這很有幫助。但你能在第四季維持那些水準嗎,抱歉,Jay?因為到那時同比基期會稍微容易一些。但這是——感覺上你們第三季交出的表現,應該能在第四季帶來持續成長,單純基於較容易的可比基期。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Well, again, we also have cyclo, which tails off a little bit in the fourth quarter. So that's a factor as we look at pure constant currency growth. So that's another element to consider.

    嗯,再說一次,我們也有 cyclo,而它在第四季會稍微走弱。所以在我們看純粹的固定匯率成長時,這是一個因素。因此這也是另一個需要考量的要素。

  • I think that as we look at the second-half growth, we feel confident in our ability to achieve it. There are some nuances between Q3 and Q4 related to timing of tenders, performance in Q4, cyclo. But on balance, I think it's consistent with what we've expected. And like I said, we feel confident in our ability to deliver it.

    我認為,當我們看下半年成長時,我們對達成它的能力感到有信心。在 Q3 與 Q4 之間有一些細微差異,與標案時點、Q4 的表現、cyclo 有關。但整體而言,我認為這與我們原先的預期一致。而且如我所說,我們對交付它的能力有信心。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Okay. And then 2 long-term questions. First, Jay, I'll start with you and then finish with Joe. So Jay, I don't know if we didn't get an EBITDA margin guidance update on this call. I think you initially had said 24% to 25%. Obviously, the EBIT margins are fantastic. So if you think about EBITDA in 2020, just given the tremendous improvements you've had on CapEx and the impacts on depreciation, how do we think about EBITDA guidance in 2020?

    好的。接著有兩個長期問題。第一個,Jay,我先問你,然後再問 Joe。所以 Jay,我不確定我們是否在這通電話中得到 EBITDA 利潤率指引的更新。我記得你一開始說的是 24% 到 25%。顯然,EBIT 利潤率非常亮眼。所以如果你思考 2020 年的 EBITDA,考量你們在 CapEx 上的巨大改善以及對折舊的影響,我們該如何看待 2020 年的 EBITDA 指引?

  • And then for Joe, I think all these questions about organic growth from the call are trying to get to sort of one question, which is, if you can do 6% operationally in the third quarter, are you really saying you're going to see some deceleration in the business intermediate-term before you get acceleration into '19 and '20? Or are we just making more of this than we should be, and these numbers may be a little conservative?

    然後對 Joe 而言,我覺得這通電話上所有關於有機成長的問題,都是想釐清一個問題:如果你們第三季在營運層面可以做到 6%,你們真的是在說,在 2019 與 2020 年加速之前,中期業務會先出現一些減速嗎?還是我們把這件事解讀得太多了,而這些數字可能只是稍微保守?

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • So let me start with my -- with your question, and Jay will talk to you about EBITDA.

    那我先從我——從你的問題開始,然後 Jay 會跟你談 EBITDA。

  • A lot of the growth on a quarter-to-quarter basis is about comps from the previous quarter. We need to look at sequential and we also need to look at sustainability. So we feel comfortable with the long term being 4% because we look at how our programs are being factored into the growth, and also the tenders that we have. Remember, we have a steady business in terms of the products that we sell. And if we are out of a tender, we're out of a tender. This is the issue that we had in Europe in the last 18 months is that we are out of some tenders because we didn't want to bid. When we get back in, it guarantees the business for the longer term.

    很多逐季的成長,取決於前一季的可比基期。我們需要看序列成長,也需要看可持續性。所以我們對長期 4% 感到放心,因為我們會看我們的方案如何被納入成長,以及我們手上的標案。記住,我們在所銷售產品方面是一個相對穩定的業務。而如果我們在某個標案中落選,我們就會失去那個標案。過去 18 個月我們在歐洲遇到的問題是,我們在一些標案中缺席,因為我們不想投標。當我們重新回到標案中時,會在較長期間內保障該業務。

  • So I feel comfortable that we are -- that the 6% is to be delivered in the quarter. But going forward, we want to make sure that we are at about a 4% level. This is because we are looking at more sequential growth and sustainable growth. We will have quarters that have higher growth and lower growth, like we just had this quarter, because of discontinuation of business. But in the meantime, we want to have that 4% there and target 5%.

    所以我對於 6% 會在該季度交付感到放心。但往前看,我們希望確保大約在 4% 的水準。這是因為我們更著眼於序列成長與可持續成長。我們會有成長較高與較低的季度,就像我們這一季一樣,因為有業務中止。但同時,我們希望維持 4% 並以 5% 為目標。

  • The delivery of our second half, we would not be giving guidance today and affirming the numbers if we couldn't do it. I'm confident about our ability to deliver on that as we speak today. However, that should not be something that the analysts should be thinking about for us going forward, okay? Because it is quarter-by-quarter, we look at more the long term.

    下半年目標的交付,如果我們做不到,我們今天就不會給出指引並重申這些數字。就我目前而言,我對我們交付的能力有信心。不過,這不應該是分析師往後在看我們時所要一直糾結的事情,好嗎?因為這是逐季的,我們更看重長期。

  • So the 4%, David, may have had an acceleration towards the end of the period that we provide you guidance with the 2020. We'll have an acceleration, so we can make that number happen based on the numbers for '18 and based on the discontinued products that we have.

    所以,David,這個 4% 可能會在我們提供到 2020 年指引的期間末端出現加速。我們會有加速,因此我們可以讓那個數字發生,基於 2018 年的數字以及我們已停產的產品。

  • I just want to also tell that -- say that this number, organically, is completely unlevered. But we continue to pursue tuck-in acquisitions that will help us on an inorganic side for the next 12 months, but also that will bring pipeline into the company and will help us with the organic going forward. So it is a combination. But right today, we're sticking to the 4%.

    我也想補充說——這個數字在有機層面完全沒有槓桿。但我們會持續尋求補強型(tuck-in)併購,在未來 12 個月於非有機面提供幫助,同時也會把產品管線帶進公司,並在未來幫助我們的有機成長。所以這是組合。但就今天而言,我們仍維持 4%。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • David, the EBITDA margin in 2020 is approximately 26%.

    David,2020 年的 EBITDA 利潤率大約是 26%。

  • Operator

    Operator

  • And our next question comes from Isaac Ro of Goldman Sachs.

    我們的下一個問題來自高盛的 Isaac Ro。

  • Isaac Ro - VP

    Isaac Ro - VP

  • First question on the long-term guidance. I was just trying to go through some of the moving parts that were yet uncovered, and one was on share count. I just want to confirm that you're assuming that you believe perhaps enough share repurchase to offset option solution, but not assuming that there'll be a meaningful net reduction in share count through 2020. Is that sort of the right way to think about it?

    第一個問題關於長期指引。我只是想梳理一些尚未被揭露的變動因素,其中一個是股數。我想確認一下,你們的假設是可能會有足夠的庫藏股回購來抵消選擇權稀釋,但並未假設到 2020 年會有顯著的淨股數下降。這樣理解對嗎?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • That's exactly right. In our model, and we have held share count flat to 2017 levels. And underlying that is an assumption about a certain amount of buyback. But the result of that, given the very strong cash flow generation of the company, is a serious positive net debt or net asset position as we look at cash relative to gross debt.

    完全正確。在我們的模型中,我們把股數維持在 2017 年的水準不變。其背後的假設是會有一定程度的回購。但在此結果之下,考量公司非常強勁的現金流創造能力,當我們比較現金相對於總負債時,會呈現顯著的淨負債為正或淨資產部位。

  • Isaac Ro - VP

    Isaac Ro - VP

  • Right, great. That's what I was getting at. And then a follow-up on just a couple of the product specifics. BioSurgery, you guys mentioned a slight decline there, but I think you've also talked a little bit about how your pretty strong pipeline is in 2018. So I'm just trying to handicap how we should take about the recovery to growth. Is it going to be sort of a sharper inflection towards this time next year? Or could we see an improvement sooner than that?

    了解,很好。這正是我想問的。接著追問幾個產品細節。BioSurgery 方面,你們提到那裡有小幅下滑,但我想你們也談到 2018 年你們相當強勁的產品管線。所以我想評估一下,我們應該如何看待恢復成長。會不會在明年這個時點附近出現較明顯的轉折?或者我們可能更早看到改善?

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • So we have a significant amount of activity going on at the end of this year and into '18 for BioSurgery. What is affecting us today is the performance of the Synovus acquisition products that were made by the company a few years ago. Those are products that are legacy. They have very little improvement to those products to be made. And what we are focusing on, our hemostat sealants base business of Baxter, which just in one category, just the FLOSEAL alone is growing 7%, okay? So that is good growth there.

    所以在今年年底到 2018 年,BioSurgery 會有相當多的活動在進行。目前影響我們的是幾年前公司所做的 Synovus 併購產品的表現。那些是既有(legacy)產品。這些產品可改進的空間非常有限。而我們的重點是 Baxter 的止血封合劑(hemostat sealants)基礎業務;僅在其中一個類別,單是 FLOSEAL 就成長 7%,好嗎?所以那裡的成長是好的。

  • So for us to return to a market growth rate, this is what we expect to do in 2018, okay? And then we will look forward to some augmentation inorganically speaking into that business, that will help us deliver more pipeline and some adjacencies into the surgery business.

    因此,對我們而言,要回到市場成長率,這是我們預期在 2018 年要做到的,好嗎?接著我們也會展望以非有機方式對該業務做一些增補,這將幫助我們帶來更多產品管線,以及在外科手術業務中的一些相鄰領域。

  • I'm quite confident in the delivery of these new products. They're not home runs. They're singles and doubles. But just reignite the innovation that the company has not delivered in the past years and just the new management into that business is really -- is stealing the innovation part quite a bit. That's why we're having so many things happening next year. We have launched of new forms of FLOSEAL, new applicators, new geographic expansions. So we'll get back into this game in a good way and beginning to see that transformations '18 in terms of getting to market growth.

    我對這些新產品的交付相當有信心。它們不是全壘打。它們是安打與二壘安打。但它們能重新點燃公司過去幾年未能交付的創新動能,而新管理團隊進入該業務,確實——在很大程度上把創新這一塊重新奪回來。這也是為什麼我們明年會有這麼多事情發生。我們已推出FLOSEAL的新劑型、新的施用器,以及新的地理區域擴張。因此,我們會以良好的方式重返這個賽局,並開始看到在2018年就市場成長而言的轉型。

  • Operator

    Operator

  • And our next question comes from Bob Hopkins of Bank of America.

    下一個問題來自美國銀行(Bank of America)的Bob Hopkins。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • So just 2 quick things, because a lot of questions have been asked. Joe, I was wondering if you could talk a little bit more about some of the leadership changes that you're referring to on this call just in terms of kind of when they happen and maybe a little bit more on the folks that you're bringing into the company. And then I have one quick one for Jay to follow up.

    我就兩個簡短的問題,因為已經問了很多了。Joe,我想請你再多談一點你在這通電話中提到的一些領導層變動,包括大概是在什麼時候發生的,以及你們引進公司的人選的一些背景。然後我還有一個簡短問題要接著問Jay。

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • Yes. Bob, we had an organization that was -- had the international businesses all concentrated under one person. When this person retired, it was an opportunity for us to really take a look and say, "I don't like to concentrate 60% of our business with very different profiles under just one person."

    是的。Bob,我們原本的組織是——把所有國際業務都集中在一個人之下。當這位人士退休時,這給了我們一個機會重新檢視並說:「我不喜歡把我們60%的業務、而且輪廓差異很大的業務,都只放在一個人之下。」

  • So bringing Americas under Brik, a very experienced leader within Baxter; and Cristiano Franzi, who worked with me before; and Andy Frye, who comes from a large distributor in Asia, and before that Abbott, will give us a great execution lever to focus on those regions instead of just have one person looking at everything but the U.S. It's just a philosophy and a proven theory that I have that when you divide the world in the right regions, you have people focused on those regions, not only the top line, but also the EPS per region.

    因此把美洲業務交由Brik負責——他是Baxter內部非常有經驗的領導者;以及Cristiano Franzi(他以前和我共事過);還有Andy Frye(他來自亞洲一家大型經銷商,在那之前在Abbott任職)——這將讓我們擁有很強的執行槓桿,能聚焦各個區域,而不是只讓一個人看所有非美國的事情。

  • The other -- Sumant is a great technology and research and development leader, comes here to the company with significant experience, as we have ambitions to continue to grow our pharmaceutical business. Sumant brings a wealth of knowledge and experience into this area. And I think The Street's familiar with him, and he worked for Hospira before and then Pfizer. We're really excited about that.

    另外——Sumant是一位很出色的技術與研發領導者,帶著相當豐富的經驗加入公司,因為我們有志於持續擴大我們的製藥業務。Sumant在這個領域帶來大量的知識與經驗。我想華爾街(The Street)對他並不陌生,他之前在Hospira任職,之後在Pfizer。我們對此非常興奮。

  • And Giuseppe moving up to have a global role in terms of managing our product franchise in terms of innovation as well as upstream marketing, and working closely with our M&A group to make sure that we have the right inorganic opportunities in place makes this team pretty strong. On top of it, we brought Dennis Crowley, who used to work for me before in M&A. Dennis really brings a strong background in acquisitions with him. There are a couple more team members that came to Baxter. So we're [augment] to what we need. You never say you're finished. There's no finishing line when you manage a company, but we think today that we confidently have a strong team amongst our peers.

    而Giuseppe升任並承擔全球角色,負責管理我們的產品事業群(franchise),涵蓋創新以及上游行銷(upstream marketing),並與我們的併購(M&A)團隊密切合作,確保我們具備正確的外生成長機會(inorganic opportunities),讓這個團隊相當強。此外,我們也延攬了Dennis Crowley,他以前在併購領域曾為我工作過。Dennis在收購方面帶來非常扎實的背景。還有幾位團隊成員也加入了Baxter。所以我們正在[augment]到我們所需要的配置。你永遠不會說自己已經完成。經營公司沒有終點線,但我們認為以今天來看,我們有信心在同業之中擁有一支強大的團隊。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Great, that's helpful. And then just to finish, Jay, previously, in your LRP, you gave specifics on 2018 and 2020 for top line growth. And we've talked a lot about top line growth here, but I'm just curious if maybe you could talk a little bit more about the cadence of operational revenue growth over the course of the LRP. And you've mentioned growing above 4% in 2020. Is there a more specific target for 2020 that you'd be willing to disclose here? And I guess, just a question on cadence.

    很好,這很有幫助。最後,Jay,先前在你們的LRP中,你對2018年與2020年的營收成長給了具體說法。我們在這裡談了很多營收成長,但我想請你再多談一點在LRP期間營運性營收成長(operational revenue growth)的節奏(cadence)。你提到2020年會成長高於4%。你是否願意在這裡披露一個更具體的2020年目標?我想問的就是節奏問題。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes. Again, for us, the relevant number is the 4% over the period. As we approach the back part of this long-range plan horizon, you start to see the impact of innovation. And annual rates ticking the 20% rate is a little bit above the 4%. And then as we look at 2018, there are a few different factors in play that impact that. You have the full -- a annualization or some part of your benefit from Claris, but you also have an assumption around cyclo competition that we will be taking. And then also the impact of innovation in 2018 is not as great as it is in the latter part of this plan period. So a number of different factors; we'll stop short, again, today of giving annual revenue guidance because, again, there's a lot of puts and takes as we approach 2018.

    是的。再次強調,對我們而言,關鍵數字是整個期間的4%。當我們接近這個長期計畫視野的後段時,你會開始看到創新的影響。而年度成長率觸及20%的水準會略高於4%。再看2018年,會有幾個不同因素影響。你會有Claris帶來的全年化——或部分全年化的效益,但同時我們也假設會面臨環磷醯胺(cyclo)的競爭。此外,2018年的創新影響不如本計畫期間後段那麼大。因此有多種因素;我們今天仍會保留,不提供年度營收指引,因為隨著接近2018年,仍有很多正反因素(puts and takes)。

  • Operator

    Operator

  • And our next question comes from Joanne Wuensch of BMO Capital Markets.

    下一個問題來自BMO Capital Markets的Joanne Wuensch。

  • Joanne Karen Wuensch - MD and Research Analyst

    Joanne Karen Wuensch - MD and Research Analyst

  • Briefly, could you please give us an idea of how the cyclophosphamide competition you expect will be annualizing over the next couple of years? You briefly mentioned the impact in '18, but you have a better line of sight on the competition than we do.

    簡單問一下,你能否讓我們了解你們預期環磷醯胺(cyclophosphamide)競爭在未來幾年會如何全年化(annualizing)?你剛才簡要提到2018年的影響,但你們對競爭態勢的能見度比我們更高。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • By 2020, we have a fairly small cyclo business. So we expect this winding down very significantly from the current level to a 2020 number. And that occurs -- starts to occur at the end of 2018 -- or 2017 as a result of incremental competition onboarding. But I will tell you, this is one that we have frankly been surprised by over the last several years. The level -- the number of competitive entrants has been fewer than we originally modeled in 2015 than we modeled again in 2016. So it's best for us to keep watching this one.

    到2020年,我們的環磷醯胺(cyclo)業務規模會相當小。因此我們預期它會從目前水準大幅下滑到2020年的水準。而這個變化——會在2018年底——或2017年底開始出現,原因是新增競爭者陸續導入(onboarding)。但我得說,坦白講,過去幾年這一點讓我們感到意外。競爭者進入的程度——進入者數量比我們在2015年最初建模時、以及2016年再次建模時都要少。所以我們最好持續觀察這一項。

  • We'll provide an update on cyclo guidance on our January earnings call certainly and, again, as we approach the balance of this year and next quarter's call. But it's hard to say what's ultimately going to happen. What I can tell you is we have a fair amount of competition that's assumed by 2020 with a fairly de minimis business left in cyclo at that point.

    我們當然會在1月的財報電話會議上更新環磷醯胺(cyclo)的指引,並且同樣地,隨著接近今年剩餘時間以及下一季的電話會議也會更新。但很難說最終會發生什麼。我能告訴你的是,到2020年我們假設會有相當程度的競爭,而屆時環磷醯胺(cyclo)剩下的業務將相當微不足道(de minimis)。

  • Joanne Karen Wuensch - MD and Research Analyst

    Joanne Karen Wuensch - MD and Research Analyst

  • That's helpful. And as my follow-up question, there's no doubt you have a lot of cash that you can deploy, and yet I feel like investors are waiting for you to do so. What does it take internally for you to pull that trigger? What kind of conversation does it -- has to happen?

    這很有幫助。作為追問,毫無疑問你們有很多現金可以運用,但我覺得投資人一直在等你們出手。在內部,要達到什麼條件你們才會扣下扳機?需要進行什麼樣的討論?

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • We have a lot of conversations. What it takes is to have the right strategic target.

    我們有很多討論。關鍵在於要有正確的策略性標的。

  • You've got to make sure that you are returning money to the shareholders. You can't just make an acquisition and think that internal rate of return of 7% is good enough. Maybe it's good enough for a few investors, for the majority of investors that is below our long-term WACC, and that is not something that I responsibly will do.

    你必須確保你是在把錢回饋給股東。你不能只是做一筆收購,然後覺得7%的內部報酬率(IRR)就夠好。也許對少數投資人來說夠好,但對大多數投資人而言,那低於我們的長期加權平均資本成本(WACC),而這不是我會負責任地去做的事。

  • We'll select the right targets, we are doing that as we speak, a significant amount of work. But I said to you, we're going to deliver value no matter what, either through acquisitions and as well through share buybacks. So I feel comfortable, both ends of the scale. We didn't discard large acquisitions at all, we are just going now after everything that we can look at that makes sense for Baxter, okay?

    我們會挑選正確的標的;我們此刻正在做這件事,投入了大量工作。但我也跟你說過,不管怎樣我們都會交付價值,無論是透過收購,或是透過庫藏股回購。所以我對兩端的選項都感到安心。我們完全沒有排除大型收購,我們只是現在會去看所有我們能看的、且對Baxter有意義的機會,好嗎?

  • With a better team in place, we're looking at a much more agile process to get to our targets and as well as the amount of balance sheet capital that we have today, the ability to raise capital in our organic way to get there. We will return money to the shareholders. So it's a win-win because we have 2 good avenues, and we can do both at the same time.

    隨著更好的團隊到位,我們正朝著更敏捷的流程邁進,以達成我們的目標;同時,憑藉我們目前擁有的資產負債表資本規模,以及以內生方式籌集資本以達成目標的能力。我們將把資金回饋給股東。因此這是雙贏,因為我們有兩條很好的途徑,而且可以同時進行。

  • Operator

    Operator

  • And our final question comes from the line of Danielle Antalffy of Leerink Partners.

    我們的最後一個問題來自 Leerink Partners 的 Danielle Antalffy。

  • Danielle Joy Antalffy - MD, Medical Supplies and Devices

    Danielle Joy Antalffy - MD, Medical Supplies and Devices

  • Jay, I was hoping you could give a little bit more color on what's driving the average -- the increase in EPS guidance. How much of that is coming from FX in the back half of the year versus Claris, versus better operational performance. And then I had one follow-up.

    Jay,我希望你能再多補充一些細節,說明是什麼在推動平均——也就是 EPS 指引的上調。其中有多少來自下半年匯率(FX)的影響,相較於 Claris,相較於更好的營運表現。然後我還有一個追問。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Sure. The prior guidance, the midpoint of the range was roughly $2.24. And as we think about the current midpoint, it moves to $2.37. There's a few drivers. The overperformance that we experienced in Q2 contributes roughly $0.07. The tax rate -- improvements in tax is roughly $0.03. Cyclophosphamide is a couple of pennies of impact. FX is $0.01, and Claris is $0.01. So if you add those up, it's roughly $0.14 versus the midpoint of the last guidance range. About half of that speaks to the Q2 performance, with the residual relating to other aspects of the business.

    當然。先前的指引區間,其中點大約是 2.24 美元。而我們看目前的中點,提升到 2.37 美元。背後有幾個驅動因素。我們在第二季(Q2)的超預期表現約貢獻 0.07 美元。稅率——稅務改善約為 0.03 美元。環磷醯胺(Cyclophosphamide)影響約為幾美分。匯率(FX)是 0.01 美元,Claris 也是 0.01 美元。因此把這些加總起來,相較於上一個指引區間的中點,約增加 0.14 美元。其中大約一半反映 Q2 的表現,其餘則與業務的其他面向相關。

  • Danielle Joy Antalffy - MD, Medical Supplies and Devices

    Danielle Joy Antalffy - MD, Medical Supplies and Devices

  • Okay, that's helpful. And then my follow-up is on long-term perspectives. Some of the higher profile pipeline products, specifically the on-demand PD product, just wondering how you see products like that coming into play and driving that 4% CAGR through 2020. I mean, how do we think about the on-demand PD product for your Renal business? Is that something that takes penetration, in your view, from 12% to 14% in the U.S. today to some number significantly higher? Is it more a pricing play? How do we think about that impacting the Renal business and how much that contributes to your long-term guidance?

    好的,這很有幫助。那我的追問是關於長期展望。一些較受矚目的管線產品,特別是按需(on-demand)的 PD 產品,我想了解你如何看待這類產品在推動 2020 年前 4% 年複合成長率(CAGR)方面所扮演的角色。也就是說,我們該如何看待按需 PD 產品對你們腎臟(Renal)業務的意義?你認為它是否能把目前美國 12% 到 14% 的滲透率提升到顯著更高的水準?還是更多是一個定價策略?我們該如何思考它對腎臟業務的影響,以及它對你們長期指引的貢獻有多少?

  • Jose E. Almeida - Chairman, CEO and President

    Jose E. Almeida - Chairman, CEO and President

  • You're welcome.

    不客氣。

  • Our on-demand product is on track. We are -- we see this as excess to PD. We have modeled the penetration and how you're going to behave in the marketplace. I think it's a little too early for us to give you that information as we're starting our clinical trials, I know, next year. And we'll be having this product on the market probably by 2020, once the clinical trial is finished.

    我們的按需產品進展如期。我們——我們將其視為 PD 的延伸。我們已對滲透率以及你們在市場上的行為方式進行建模。我認為現在還稍早,因為我們將在明年開始臨床試驗,所以還不便提供那些資訊。而一旦臨床試驗完成,我們大概會在 2020 年把這個產品推向市場。

  • The plans that I've seen, I've seen a rapid succession of improvements to the product, which makes me very happy in terms of R&D agility and continue to improve the product as it launches. Our philosophy today versus the old one is, we launch products faster with possibility of improvement as we go along to provide more value to the customer instead of getting and waiting for the optimal product with the most features to come out, because what we find is highly featured products are not the way forward for an efficient health care system.

    就我看到的計畫而言,我看到產品在短時間內快速連續地改良,這讓我非常高興,因為這代表研發(R&D)的敏捷性,並且能在產品上市後持續改進。我們現在的理念相較於過去是:更快推出產品,並在推進過程中保留改良的可能性,以便為客戶提供更多價值;而不是為了等到最優、功能最齊全的產品才推出,因為我們發現,高度堆疊功能的產品並不是邁向高效率醫療體系的方向。

  • So we want to make sure that we have in the product what is needed, and not what all the features that we could engineer and put into the product. So we are confident that this product is going to do a few things for us. One is increase the penetration of PD for the ease-of-use. Not everybody would like to receive a palliative product every month.

    因此我們希望確保產品具備「需要的」內容,而不是把所有我們能工程化、能塞進產品的功能都放進去。所以我們有信心這個產品將為我們帶來幾件事。第一,是因為更容易使用而提升 PD 的滲透率。並不是每個人都願意每個月收到一個緩和治療(palliative)產品。

  • The second thing is a product that eventually can customize a solution concentration. This is not how we're coming out known to the market with, but it's eventually you can get there.

    第二,是這個產品最終可以客製化溶液濃度。這不是我們一開始對市場推出時就具備的功能,但最終是可以做到的。

  • Thirdly is also cost savings for the company in terms of the logistics costs of moving fluid around. So -- but we're factoring that alongside our AMIA introduction, which happened last year. So what happens is a sequential of innovation for PD. And our end objective is to make sure that as many patients that can receive PD are receiving PD in their homes. That's our main objective, because we know the therapy is equally efficient as HD, but also provide a better life experience for the patient, who then can work during the day and do -- be productive during the day.

    第三,對公司而言也能在物流成本上節省,因為可以減少搬運液體的物流費用。所以——但我們也把這點與我們去年推出的 AMIA 一併納入考量。因此會形成 PD 的連續創新。而我們的最終目標,是確保盡可能多適合接受 PD 的病患,都能在家中接受 PD。這是我們的主要目標,因為我們知道這種療法的效率與血液透析(HD)同樣有效,同時也能為病患帶來更好的生活體驗,讓他們白天可以工作並——在白天保持生產力。

  • So we are a little too early to give you the numbers. When we are ready, when we're close to the end of the clinical trial, we'll have more numbers in terms of penetration and how we're going to do this introduction. But we're very confident in talking to the FDA. The FDA is working with us, very interested, as a matter of fact, how they can help move this technology forward. Thank you.

    所以現在要給你具體數字還稍早。等我們準備好、接近臨床試驗尾聲時,我們會有更多關於滲透率以及我們將如何導入上市的數據。但我們與 FDA 的溝通讓我們非常有信心。FDA 正與我們合作,而且非常感興趣;事實上,他們也在思考如何協助推動這項技術向前發展。謝謝。

  • Operator

    Operator

  • Thank you. And that concludes our question-and-answer session for today. Ladies and gentlemen, this does conclude today's conference with Baxter International. Thank you for participating, and have a great day.

    謝謝。以上為我們今天的問答環節。各位女士、先生,百特國際(Baxter International)今天的電話會議到此結束。感謝各位參與,祝各位有美好的一天。